Brief Summary

Provide pre-approval single patient Expanded Access (compassionate use) of abrocitinib for patients with severe uncontrolled atopic dermatitis

Detailed Description

Expanded Access requests from treating physicians may be submitted at www.pfizercares.com ;

availability will depend on location/country.

Available
Individual Patients
Severe Uncontrolled Atopic Dermatitis

Drug: abrocitinib

Eligibility Criteria

Must have severe uncontrolled atopic dermatitis refractory to other available treatments

Eligibility Gender
All
Eligibility Age
Minimum: 12 Years
Contacts
Pfizer
In Expanded Access, treating physicians are the Sponsor
NCT Number
Keywords
atopic dermatitis
AD
Atopic eczema
JAK inhibitors
MeSH Terms
Dermatitis, Atopic
Dermatitis
Eczema
Abrocitinib